Shots:

• The data included results from the ongoing long-term extension (LTE) P-1b study of aducanumab for the treatment of Alzheimer Disease
•  The results for each dose are same as interimanalyses showing decreasing level of amyloid plaque when measured with PET- in dose and time-dependent manner in titration and FD cohorts
• The study (N=196) patients receives aducanumab or PBO and (143/196) entered into LTE cohorts with six arms: PBO switchers- 1mg/kg switcher to 3 mg/kg- FD (3- 6- 10 mg/kg) and titration- having a duration of 36 mos in titration and 48 mos in FD cohorts

       Ref: Biogen | Image:  Biogen